Tactile Medical expects 8%-11% revenue growth in 2026 while expanding integrated lymphedema solutions

Earnings Call Insights: Tactile Systems Technology, Inc. (TCMD) Q4 2025

MANAGEMENT VIEW

* CEO Sheri Dodd highlighted 2025 as a pivotal year, stating that "Through disciplined execution across our commercial and operational strategies, we delivered strong profitable revenue growth while continuing to make critical investments in people and workflow-related processes." She reported total revenue for the full year of $329.5 million, a 12% increase year-over-year, and full-year gross margins of 75.9%. Dodd detailed the repayment of $26.3 million in term loans and $26.5 million in stock repurchases, ending the year with $83.4 million in cash and operating cash flow close to $43 million.
* Dodd announced the acquisition of LymphaTech, describing it as "an exciting milestone in Tactile's evolution from a product-based company to a comprehensive integrated lymphedema solutions leader," and emphasized its potential for accelerating accurate disease identification and therapy access.
* The company’s 2026 revenue guidance is set at $357 million to $365 million, representing 8%-11% year-over-year growth. Dodd mentioned this incorporates "a potential short-term market impact from the recently announced Medicare prior authorization requirement for pneumatic compression devices."
* CFO Elaine Birkemeyer stated, "Total revenue in the fourth quarter increased by $80 million or 21% to $103.6 million." She also noted, "gross margin was 78.2% of revenue compared to 75.2% in the fourth quarter of 2024."

OUTLOOK

* For 2026, management projects total revenue between $357 million and $365 million, with expected growth of 8%-11%. Both lymphedema and airway clearance businesses are expected to grow in a similar range, with airway clearance growing modestly faster.
* The guidance accounts for a new Medicare prior authorization requirement for pneumatic compression devices, starting April 13, which management expects will have a "temporary short-term impact across the broader lymphedema market."
* Birkemeyer explained, "We expect our GAAP gross margin to be approximately 76%, our GAAP operating expenses to increase 8% to 10% year-over-year... net interest income of approximately $3 million, a tax rate of 28% and a fully diluted weighted average share count of approximately 22 million to 23 million shares." Adjusted EBITDA is expected to be $49 million to $51 million in 2026.

FINANCIAL RESULTS

* Tactile Medical delivered Q4 revenue of $103.6 million, with lymphedema revenue at $89.5 million and airway clearance revenue at $14.1 million. Net income rose to $10.6 million, or $0.46 per diluted share. Adjusted EBITDA increased to $22 million.
* The company ended 2025 with $83.4 million in cash and no outstanding borrowings.
* Gross margin expanded to 78.2% in Q4, attributed to lower manufacturing costs and stronger collections.

Q&A

* Kyle Edward Winborne, Piper Sandler: Asked about drivers of Q4 lymphedema performance and the impact of NCD interpretation. Dodd responded that "multiple investments in people and processes and technology... really enabled the company to outperform expectations," citing strong CRM adoption, increased rep hiring, and modest tailwinds from Medicare patients moving directly to Flexitouch.
* Winborne further inquired about balancing headwinds from new Medicare requirements with tailwinds. Dodd said, "our outlook... incorporates a very balanced and thoughtful approach," noting readiness for prior authorizations and expectation of only a short-term headwind.
* Iseult McMahon, BTIG: Requested color on the LymphaTech acquisition and its commercialization. Dodd explained, "they already have a commercialized product," and detailed plans to integrate LymphaTech into Tactile’s commercial engine, while working on regulatory and reimbursement strategies.
* McMahon also asked what could drive the lower or upper end of guidance. Dodd said, "an 8% would be the prior auth is really challenging," but emphasized that underlying business fundamentals remain strong.
* Brandon Vazquez, William Blair: Queried how prior authorization might affect CMS patient process times. Birkemeyer described, "the process is you curate a package... and that is submitted," noting it could "elongate the process" but expressing confidence in adaptation and technology support. Vazquez also asked about EBITDA leverage, with Birkemeyer highlighting "really good discipline from a cost management perspective as well as starting to see benefit from those investments that we've been making."
* Benjamin Haynor, Lake Street Capital Markets: Asked for clarification on CMS requirements and potential impact of bronchiectasis drug launches. Birkemeyer said, "we have a good understanding of what Medicare is looking for a successful claim," and Dodd acknowledged increased disease awareness and market growth as positive factors.

SENTIMENT ANALYSIS

* Analysts were generally positive, focusing on strong Q4 performance, the integration of LymphaTech, and balancing reimbursement headwinds. Questions sought clarity on operational readiness and the timeline for navigating Medicare changes, with a constructive tone.
* Management maintained a confident and composed tone, providing detailed responses and reiterating readiness for policy shifts. Dodd repeatedly emphasized the company’s preparedness, stating, "we are prepared, we will address this," and Birkemeyer expressed optimism around leveraging new technology for operational efficiency.
* Compared to the previous quarter, both analysts and management reflected heightened confidence, with less focus on past headwinds and more on execution and future strategy.

QUARTER-OVER-QUARTER COMPARISON

* Guidance was raised from $317-$321 million for 2025 in Q3 to a new range of $357-$365 million for 2026, reflecting ongoing commercial momentum and strategic investments.
* Strategic focus shifted from recovering Medicare headwinds and sales rep expansion in Q3 to integration of digital diagnostics (LymphaTech) and adapting to Medicare prior authorization in Q4.
* Gross margin improved from 76% in Q3 to 78.2% in Q4, and adjusted EBITDA increased from $14.4 million in Q3 to $22 million in Q4.
* Analyst interest moved from sales force expansion and product adoption in Q3 to operational readiness for reimbursement changes and leveraging new acquisitions in Q4.
* Management’s confidence in guidance and strategic initiatives increased, while analyst questions became more forward-looking and integration-focused.

RISKS AND CONCERNS

* The main challenge identified is the new Medicare prior authorization requirement for pneumatic compression devices, which could cause a temporary slowdown in market growth as the industry adjusts.
* Management’s mitigation strategy includes leveraging experience from commercial prior authorizations and deploying new AI-enabled technologies to improve workflow efficiency and response times.
* Dodd acknowledged, "we are prepared, we will address this," signaling confidence in navigating the transition.

FINAL TAKEAWAY

Management underscored strong financial performance, robust commercial execution, and continued investments in technology and workflow optimization as drivers for future growth. The acquisition of LymphaTech marks a strategic milestone, positioning Tactile Medical as a comprehensive solutions leader in lymphatic dysfunction. Despite acknowledging a temporary headwind from new Medicare prior authorization requirements, management remains confident in its ability to deliver growth in line with the market and sees multiple catalysts ahead to sustain momentum through 2026 and beyond.

Read the full Earnings Call Transcript [https://seekingalpha.com/symbol/tcmd/earnings/transcripts]

MORE ON TACTILE SYSTEMS TECHNOLOGY

* Tactile Systems Technology, Inc. (TCMD) Q4 2025 Earnings Call Transcript [https://seekingalpha.com/article/4871207-tactile-systems-technology-inc-tcmd-q4-2025-earnings-call-transcript]
* Tactile Systems Technology GAAP EPS of $0.46 beats by $0.02, revenue of $103.6M beats by $9.8M [https://seekingalpha.com/news/4552850-tactile-systems-technology-gaap-eps-of-0_46-beats-by-0_02-revenue-of-103_6m-beats-by-9_8m]
* Seeking Alpha’s Quant Rating on Tactile Systems Technology [https://seekingalpha.com/symbol/TCMD/ratings/quant-ratings]
* Historical earnings data for Tactile Systems Technology [https://seekingalpha.com/symbol/TCMD/earnings]
* Financial information for Tactile Systems Technology [https://seekingalpha.com/symbol/TCMD/income-statement]